Tumor-derived VEGF induces depletion of hematopoietic cells from bone marrow and results in an anemic symptom in VEGF tumor-bearing mice, and it can be reversed by anti-VEGF or anti-VEGFR2 therapy [32–33]. Here, VEGFA is linked to neoplasm.